Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?

被引：0
|
作者：
Ling, James [1 ]
Chow, Elaine [1 ,2 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Phase Clin Trial Ctr 1, Hong Kong, Peoples R China
来源：
MED | 2024年 / 5卷 / 08期
关键词：
D O I：
10.1016/j.medj.2024.06.010
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Previously, no randomized controlled trials investigated the renoprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) as the primary endpoint in patients with diabetes and chronic kidney disease. In the FLOW trial, Perkovic et al. showed that once-weekly semaglutide reduced kidney failure, kidneyrelated death, and cardiovascular death by 24% as compared with placebo in patients with type 2 diabetes at high risk of renal progression.
引用
收藏
页码：845 / 847
页数：3
相关论文
共 50 条
  • [41] Benefits of Glucagon-Like Peptide 1 Receptor Agonists in Kidney Transplant Recipients
    Garcia, Valencia Oscar Alejandro
    Sahi, Sukhdeep Singh
    Na, Jie
    Smith, Byron H.
    Budhiraja, Pooja
    Diwan, Tayyab S.
    Issa, Naim S.
    Denic, Aleksandar
    Abdelrheem, Ahmed
    Wadei, Hani
    Kudva, Yogish C.
    Kukla, Aleksandra
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [42] Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus A Role in Cardiovascular Disease
    Smilowitz, Nathaniel R.
    Donnino, Robert
    Schwartzbard, Arthur
    CIRCULATION, 2014, 129 (22) : 2305 - 2312
  • [43] Nonpeptidic glucagon-like peptide 1 receptor agonists: A magic bullet for diabetes?
    Murphy, K. G.
    Bloom, S. R.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (03) : 689 - 690
  • [44] Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
    Resnick, Ortal
    Bril, Fernando
    Beauchamp, Giovanna
    FRONTIERS IN ENDOCRINOLOGY, 2025, 15
  • [45] Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression
    Holliday Jr, Michael W.
    Frost, Livia
    Navaneethan, Sankar D.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2024, 33 (03): : 331 - 336
  • [46] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
    Wang, Wenwen
    Mei, Aihua
    Qian, Hang
    Li, Dongfeng
    Xu, Hao
    Chen, Jishun
    Yang, Handong
    Min, Xinwen
    Li, Chunlei
    Cheng, Li
    Chen, Jun
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2023, 18 : 129 - 137
  • [47] Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus
    Cohen, Talia Diker
    Rudman, Yaron
    Turjeman, Adi
    Akirov, Amit
    Steinmetz, Tali
    Calvarysky, Bronya
    Dotan, Idit
    DIABETES & METABOLISM, 2025, 51 (03)
  • [48] Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future
    Filipe Ferrari
    Rafael S. Scheffel
    Vítor M. Martins
    Raul D. Santos
    Ricardo Stein
    American Journal of Cardiovascular Drugs, 2022, 22 : 363 - 383
  • [49] Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
    Desai, Aakash
    Petrov, Jessica
    Hashash, Jana G.
    Patel, Harsh
    Brahmbhatt, Bhaumik
    Kochhar, Gursimran S.
    Farraye, Francis A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (05) : 620 - 632
  • [50] Glucagon-like peptide-1 receptor agonists decreases albuminuria in overweight patients with type 2 diabetes
    Bulum, T.
    Blaslov, K.
    Tomic, M.
    Duvnjak, L.
    DIABETOLOGIA, 2015, 58 : S532 - S533
12345